SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-23-012498
Filing Date
2023-04-17
Accepted
2023-04-17 14:43:53
Documents
13
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 67296
2 ex32-1.htm EX-32.1 10495
  Complete submission text file 0001493152-23-012498.txt   295261

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ptix-20221231.xsd EX-101.SCH 3233
4 XBRL LABEL FILE ptix-20221231_lab.xml EX-101.LAB 36257
5 XBRL PRESENTATION FILE ptix-20221231_pre.xml EX-101.PRE 23750
7 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 5822
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

IRS No.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-12555 | Film No.: 23823665
SIC: 2834 Pharmaceutical Preparations